

58. (New) The immunogenic composition according to claim 57 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

59. (New) The composition according to claim 57, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Sippic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.


*b3*  
*Conf*  
~~59.~~ (New) The composition of claim 59, wherein said cytokine is selected from the group consisting of GM-CSF and Flt3-ligand.

#### REMARKS

The non-elected claims 2 and 10-45 have been cancelled. Claims 3-5 and 8-9 have been cancelled from the application and claims 1, 6, and 7 have been amended. New claims 46-60 have been added. Support for all the above amendments may be found throughout the specification as originally filed and none of the amendments constitutes new matter. In particular, support for amino acids 1-249 of WT1 can be found on page 52, line 23.

Following this amendment, Claims 1, 6, 7, and 46-60 are under examination. Favorable consideration of the present application in view of the above amendment is respectfully requested.

Respectfully submitted,  
 Alexander Gaiger et al.  
 Seed Intellectual Property Law Group PLLC

  
 Julie A. Urvater, Ph.D., Patent Agent  
 Registration No. 50,461

Enclosure:

Postcard  
 701 Fifth Avenue, Suite 6300  
 Seattle, Washington 98104-7092  
 Phone: (206) 622-4900  
 Fax: (206) 682-6031  
 C:\NrPortbl\iManage\JULIEU\304046\_1.DOC

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Non-elected claims 2 and 10-45 have been canceled.

Claims 3-5 and 8-9 have been canceled.

New Claims 46-60 have been added.

Claims 1, 6, and 7 have been amended as follows:

1. (Amended) A polypeptide comprising an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the polypeptide comprises the polypeptide set forth in SEQ ID NO:144,~~no more than 16 consecutive amino acid residues present within a native WT1 polypeptide~~.

6. (Amended) A polypeptide according to claim 1, wherein the polypeptide comprises 4-16~~9~~ consecutive amino acids of a native WT1 polypeptideSEQ ID NO:144.

7. (Amended) A polypeptide according to claim 1, wherein the polypeptide comprises 8-10~~9~~ consecutive amino acids of SEQ ID NO:144a native WT1 polypeptide.